Table 1.
Time to progression in different patient subgroups [57]
| Subgroup | Letrozole | Tamoxifen | |
|---|---|---|---|
| Dominant disease site: soft tissue | n | 113 | 115 |
| Median TTP | 12.1 months | 6.4 months | |
| Dominant disease site: bone | n | 145 | 131 |
| Median TTP | 9.5 months | 6.3 months | |
| Dominant disease site: viscera | n | 195 | 208 |
| Median TTP | 8.3 months | 4.6 months | |
| Patients who had received prior Antiestrogen | n | 84 | 83 |
| Median TTP | 8.9 months | 5.9 months | |
| Hazard ratio (95% CI)a | 0.60 (0.43, 0.84) | ||
| HR-positive | n | 294 | 305 |
| Median TTP | 9.4 months | 6.0 months | |
| Hazard ratio (95% CI)a | 0.69 (0.58, 0.83) | ||
| HR-unknown | n | 159 | 149 |
| Median TTP | 9.2 months | 6.0 months | |
| Hazard ratio (95% CI)a | 0.77 (0.60, 0.99) | ||
TTP, time to progression; CI, confidence interval; HR, hormone receptor
aHazard ratios <1.0 indicate superiority for letrozole relative to tamoxifen